[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][N][Branch2][Ring1][O][C][C][N][Ring1][=Branch1][C][C][C][C][C][=C][N][C][=C][Ring1][Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][#N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=Branch1][Ring2][=C][Ring1][#Branch1][C][=Branch1][C][=O][N]"}, {"from": "gpt", "value": "The molecule is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011."}]